Dear Colleague
The first update of concessionary prices were granted today for August 2023:
DrugPack SizeConcessionary Price
Acamprosate 333mg gastro-resistant tablets168£23.80
Aciclovir 800mg tablets35£4.19
Atorvastatin 40mg tablets28£2.38
Bicalutamide 150mg tablets28£3.79
Bisacodyl 5mg gastro-resistant tablets60£4.40
Brinzolamide 10mg/ml / Timolol 5mg/ml eye drops5£8.19
Brinzolamide 10mg/ml eye drops5£4.65
Bumetanide 1mg tablets28£2.77
Buprenorphine 8mg sublingual tablets sugar free7£4.24
Calcipotriol 0.005% / Betamethasone dipropionate
0.05% ointment
30£10.09
Carbocisteine 250mg/5ml oral solution300£6.90
Carvedilol 6.25mg tablets28£1.39
Clotrimazole 1% cream20£2.10
Clotrimazole 1% cream50£3.99
Co-careldopa 25mg/100mg tablets100£6.95
Codeine 30mg tablets28£1.08
Codeine 30mg tablets100£3.85
Doxycycline 100mg capsules8£0.95
Flecainide 100mg tablets60£3.85
Flucloxacillin 250mg/5ml oral solution sugar free100£3.51
Hydroxychloroquine 200mg tablets60£3.98
Ivabradine 2.5mg tablets56£45.95
Lamotrigine 100mg tablets56£2.18
Lansoprazole 15mg orodispersible tablets28£2.88
Latanoprost 50micrograms/ml eye drops2.5£1.88
Levetiracetam 100mg/ml oral solution sugar free300£10.41
Lofepramine 70mg tablets56£13.51
Mometasone 0.1% ointment30£4.14
Mycophenolate mofetil 500mg tablets50£7.30
Oxycodone 5mg/5ml oral solution sugar free250£9.60
Perindopril erbumine 4mg tablets30£1.42
Perindopril erbumine 8mg tablets30£1.64
Pizotifen 1.5mg tablets28£1.81
Prochlorperazine 5mg tablets28£1.96
Risperidone 500microgram tablets20£3.25
Ropinirole 250microgram tablets12£5.99
Rosuvastatin 10mg tablets28£1.18
Rosuvastatin 40mg tablets28£1.70
Spironolactone 100mg tablets28£4.72
Spironolactone 25mg tablets28£1.84
Spironolactone 50mg tablets28£3.99
Tamsulosin 400microgram modified-release capsules30£1.64
Terbinafine 1% cream15£3.08
Terbinafine 1% cream30£6.71
Zopiclone 3.75mg tablets28£1.83
Zopiclone 7.5mg tablets28£1.70

Concessionary prices will be paid against the usual code, no additional endorsements are needed.

Please continue to notify CPNI of any pricing issues you are experiencing via our new Medicine Shortage Reporter.

Concessionary prices are also published on the CPNI website.

Kind regards

SENT ON BEHALF OF
GERARD GREENE
Chief Executive
Dear Contractor
The Department of Health has issued (16 August 2023) an update in respect of Serious Shortage Protocol SSP056 relating to Utrogestan 100mg capsules here.

SUMMARY

Contractors should note the following:

The expiry date for SSP056 (Utrogestan 100mg capsules) has now been extended until Friday 1 September 2023.

Contractors are reminded of the details contained within this letter relating to the decision pathways for these SSPs; notification of GPs; the need for patient/carer agreement, and action to take when this is not given; professional judgement; and actions regarding unclear quantities.

ACTION

Contractors should:

  • Read the attached letter and ensure that their dispensing teams are fully apprised of the update to SSP056.
  • Note that the latest versions of these SSPs are now available on the Business Services Organisation dedicated page on its website HERE.

CPNI colleagues will continue to keep you up to date on any further SSP issue.

Kind regards

Mike

SENT ON BEHALF OF
PROF MIKE MAWHINNEY
Head of Regulatory Affairs

Dear Contractor
Correspondence was issued by the Chief Pharmaceutical Officer on 10th August 2023 regarding arrangements for foundation training year in 2025/26.

SUMMARY

The CPO’s letter provides information for contractors regarding the placement of FTY trainees from 2025/26 onwards.

ADVICE

Contractors should review the CPO correspondence and take note of the information.

Kind regards

SENT ON BEHALF OF
GERARD GREENE
Chief Executive
This update contains important information for community pharmacy teams.

CPNI ALERTS

DOH(NI) ALERTS

BSO ALERTS

  • Weekly Drug Alerts are available here.
  • Weekly Shortages Information is available here.
  • Serious Shortage Protocols are available here.
Deafblind UK is a charity which supports people living with sight and hearing loss by providing practical support, help with technology, and advice.  The charity has asked if CPNI could share information about these services with the community pharmacy network, further information is available here and on their website.
Pharmacy team(s) can keep updated via CPNI’s Contractor Calendar and Contractor Emails.
Or report medicine shortages, pricing and staffing issues via the CPNI’s Medicine Shortage Reporter and Situation Reporter.
Please bring this to the attention of your pharmacy team(s).

Kind regards

SENT ON BEHALF OF
Gerard Greene
Chief Executive
Dear Contractor
CPNI is aware that a small number of Foundation Training Year (FTY) pharmacists who have met the criteria for registration with the Pharmaceutical Society of Northern Ireland and who have applied for their name to be entered into the register of pharmacists, have not been registered on the date which they anticipated.

Contractors are advised to bring this to the attention of any FTY pharmacist they employ and to advise them to ensure that they are appropriately registered before commencing work as a pharmacist.

Kind regards

SENT ON BEHALF OF
GERARD GREENE
Chief Executive
This update contains important information for community pharmacy teams.

CPNI ALERTS

DOH(NI) ALERTS

BSO ALERTS

Glaucoma UK Training

CPNI have been contacted by Glaucoma UK regarding a free training programme available to pharmacy teams.  The aim of the training is to equip pharmacy staff with the skills to help patients manage their glaucoma.  The attached flyer provides further information and may be shared with relevant members of the pharmacy team.  Further information on the work of Glaucoma UK is available on their website here.

Pharmacy team(s) can keep updated via CPNI’s Contractor Calendar and Contractor Emails.
Or report medicine shortages, pricing and staffing issues via the CPNI’s Medicine Shortage Reporter and Situation Reporter.
Please bring this to the attention of your pharmacy team(s).

Kind regards

SENT ON BEHALF OF
Gerard Greene
Chief Executive